Trial Profile
A clinical trial to investigate MRI and C-reactive protein levels at baseline as predictors of response to etanercept in patients with non-radiographic axial spondyloarthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2016
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis
- Focus Therapeutic Use
- 08 Feb 2016 New trial record
- 11 Nov 2015 Primary endpoint 'ASAS40' has been met, according to results presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.